JP2020504078A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020504078A5 JP2020504078A5 JP2019523865A JP2019523865A JP2020504078A5 JP 2020504078 A5 JP2020504078 A5 JP 2020504078A5 JP 2019523865 A JP2019523865 A JP 2019523865A JP 2019523865 A JP2019523865 A JP 2019523865A JP 2020504078 A5 JP2020504078 A5 JP 2020504078A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- set forth
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 27
- 102000036639 antigens Human genes 0.000 claims description 27
- 108091007433 antigens Proteins 0.000 claims description 27
- 239000012634 fragment Substances 0.000 claims description 27
- 206010006895 Cachexia Diseases 0.000 claims description 21
- 102000005861 leptin receptors Human genes 0.000 claims description 18
- 108010019813 leptin receptors Proteins 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 10
- 101001129927 Homo sapiens Leptin receptor Proteins 0.000 claims description 9
- 102000007318 human leptin receptor Human genes 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 230000011664 signaling Effects 0.000 claims description 8
- 102000016267 Leptin Human genes 0.000 claims description 7
- 108010092277 Leptin Proteins 0.000 claims description 7
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 7
- 229940039781 leptin Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims description 4
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 230000001430 anti-depressive effect Effects 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000036528 appetite Effects 0.000 claims description 2
- 235000019789 appetite Nutrition 0.000 claims description 2
- 239000002948 appetite stimulant Substances 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 239000002981 blocking agent Substances 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 229940043355 kinase inhibitor Drugs 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000004220 muscle function Effects 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 102200052962 rs1137101 Human genes 0.000 claims description 2
- 239000000021 stimulant Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 38
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 3
- 229910052802 copper Inorganic materials 0.000 claims 3
- 239000010949 copper Substances 0.000 claims 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 description 8
- 238000000034 method Methods 0.000 description 6
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- 101001063991 Homo sapiens Leptin Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 102000049953 human LEP Human genes 0.000 description 3
- 238000003556 assay Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021206917A JP2022031969A (ja) | 2016-11-08 | 2021-12-21 | レプチン受容体をアンタゴナイズする抗原結合性タンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662419062P | 2016-11-08 | 2016-11-08 | |
| US62/419,062 | 2016-11-08 | ||
| PCT/US2017/060690 WO2018089532A1 (en) | 2016-11-08 | 2017-11-08 | Antigen-binding proteins that antagonize leptin receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021206917A Division JP2022031969A (ja) | 2016-11-08 | 2021-12-21 | レプチン受容体をアンタゴナイズする抗原結合性タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020504078A JP2020504078A (ja) | 2020-02-06 |
| JP2020504078A5 true JP2020504078A5 (enExample) | 2020-12-10 |
| JP7042816B2 JP7042816B2 (ja) | 2022-03-28 |
Family
ID=60409473
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019523865A Active JP7042816B2 (ja) | 2016-11-08 | 2017-11-08 | レプチン受容体をアンタゴナイズする抗原結合性タンパク質 |
| JP2021206917A Pending JP2022031969A (ja) | 2016-11-08 | 2021-12-21 | レプチン受容体をアンタゴナイズする抗原結合性タンパク質 |
| JP2023076083A Active JP7611292B2 (ja) | 2016-11-08 | 2023-05-02 | レプチン受容体をアンタゴナイズする抗原結合性タンパク質 |
| JP2024088870A Pending JP2024109952A (ja) | 2016-11-08 | 2024-05-31 | レプチン受容体をアンタゴナイズする抗原結合性タンパク質 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021206917A Pending JP2022031969A (ja) | 2016-11-08 | 2021-12-21 | レプチン受容体をアンタゴナイズする抗原結合性タンパク質 |
| JP2023076083A Active JP7611292B2 (ja) | 2016-11-08 | 2023-05-02 | レプチン受容体をアンタゴナイズする抗原結合性タンパク質 |
| JP2024088870A Pending JP2024109952A (ja) | 2016-11-08 | 2024-05-31 | レプチン受容体をアンタゴナイズする抗原結合性タンパク質 |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10550192B2 (enExample) |
| EP (2) | EP4613772A3 (enExample) |
| JP (4) | JP7042816B2 (enExample) |
| KR (1) | KR102563568B1 (enExample) |
| CN (1) | CN110167965A (enExample) |
| AU (2) | AU2017359439B2 (enExample) |
| CA (1) | CA3043365A1 (enExample) |
| CL (3) | CL2019001263A1 (enExample) |
| CO (1) | CO2019004672A2 (enExample) |
| DK (1) | DK3538554T3 (enExample) |
| EA (1) | EA201991075A1 (enExample) |
| ES (1) | ES3040144T3 (enExample) |
| FI (1) | FI3538554T3 (enExample) |
| HR (1) | HRP20251165T1 (enExample) |
| IL (2) | IL266426B (enExample) |
| LT (1) | LT3538554T (enExample) |
| MA (1) | MA45801B1 (enExample) |
| MX (2) | MX2019005397A (enExample) |
| MY (2) | MY191256A (enExample) |
| PH (1) | PH12019500988A1 (enExample) |
| PL (1) | PL3538554T3 (enExample) |
| PT (1) | PT3538554T (enExample) |
| RS (1) | RS67214B1 (enExample) |
| SG (1) | SG10201913470SA (enExample) |
| SI (1) | SI3538554T1 (enExample) |
| SM (1) | SMT202500327T1 (enExample) |
| UA (1) | UA127678C2 (enExample) |
| WO (1) | WO2018089532A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI752920B (zh) | 2015-10-12 | 2022-01-21 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| EP4613772A3 (en) | 2016-11-08 | 2025-12-24 | Regeneron Pharmaceuticals, Inc. | Antigen-binding proteins that antagonize leptin receptor |
| CN111542540A (zh) | 2017-12-18 | 2020-08-14 | 瑞泽恩制药公司 | 结合瘦蛋白受体和/或gp130的双特异性抗原结合分子及其使用方法 |
| HRP20250986T1 (hr) | 2018-04-06 | 2025-10-24 | Regeneron Pharmaceuticals, Inc. | Antitijelo agonista leptinskog receptora za upotrebu u povećanju koštane mase kod osobe koja pati od metaboličke disfunkcije ili hipoleptinemije |
| WO2020016160A1 (en) * | 2018-07-16 | 2020-01-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat neurological diseases |
| WO2020131910A1 (en) | 2018-12-18 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for enhancing body weight and lean muscle mass using antagonists against leptin receptor, gdf8 and activin a |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| EP4180020A4 (en) * | 2020-07-17 | 2024-08-07 | Sumitomo Seika Chemicals Co., Ltd. | ABSORBER |
| AU2021343444A1 (en) * | 2020-09-15 | 2023-04-20 | Regeneron Pharmaceuticals, Inc. | Use of lepr agonists for pain |
| CN118436632B (zh) * | 2024-07-05 | 2024-08-30 | 四川大学华西第二医院 | Teriflunomide在制备预防和/或治疗原发性纤毛不动综合征的药物中的用途 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6451523B1 (en) | 1994-09-14 | 2002-09-17 | Interneuron Pharmaceuticals, Inc. | Detection of a leptin receptor variant and methods for regulating obesity |
| US5912123A (en) | 1994-09-14 | 1999-06-15 | Progenitor, Inc. | Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology |
| US5856098A (en) | 1994-09-14 | 1999-01-05 | Progenitor, Inc. | Detection of a leptin receptor variant |
| US5643748A (en) | 1994-09-14 | 1997-07-01 | Progenitor, Inc. | HU-B1.219, a novel human hematopoietin receptor |
| US6977240B1 (en) | 1995-11-27 | 2005-12-20 | Millenium Pharmaceuticals, Inc. | Methods of using the OB receptor antibodies to treat bodyweight disorders |
| US6482927B1 (en) | 1995-11-27 | 2002-11-19 | Millennium Pharmaceuticals, Inc. | Chimeric proteins comprising the extracellular domain of murine Ob receptor |
| US20050019325A1 (en) | 1996-01-08 | 2005-01-27 | Carter Paul J. | WSX receptor agonist antibodies |
| WO1997025425A1 (en) | 1996-01-08 | 1997-07-17 | Genentech, Inc. | Wsx receptor and ligands |
| AU2476301A (en) | 1996-01-16 | 2001-05-24 | Rockefeller University, The | DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof |
| US7063958B1 (en) * | 1996-01-16 | 2006-06-20 | The Rockefeller University | Nucleic acids db, the receptor for leptin |
| AU1833197A (en) | 1996-01-18 | 1997-08-11 | Progenitor, Inc. | Detection of a leptin receptor variant and methods for regulating obesity |
| DK0892849T3 (da) | 1996-01-23 | 2006-07-24 | Indevus Pharmaceuticals Inc | Fremgangsmåde til anvendelse af obese-genet og dets genprodukt til stimulering af hæmatopoietisk udvikling |
| US7067472B1 (en) | 1996-06-04 | 2006-06-27 | The Scripps Research Institute | Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies |
| US5965521A (en) | 1997-02-25 | 1999-10-12 | Eli Lilly Company | Pulsatile delivery of leptin receptor ligands |
| IL120733A0 (en) | 1997-04-29 | 1997-08-14 | Yeda Res & Dev | Leptin as an inhibitor of cell proliferation |
| US6696411B1 (en) | 1998-04-22 | 2004-02-24 | Cornell Research Foundation, Inc. | Canine erythropoietin gene and recombinant protein |
| AU767068B2 (en) | 1999-06-11 | 2003-10-30 | Baylor College Of Medicine | Methods and compositions for control of bone formation via modulation of leptin activity |
| US20040253242A1 (en) | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
| FR2852397B1 (fr) | 2003-03-10 | 2005-04-29 | Utilisation des genes leprotl 1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal. | |
| ATE364630T1 (de) * | 2003-08-21 | 2007-07-15 | Vlaams Interuniv Inst Biotech | Neuer leptin-antagonist |
| DE10353593A1 (de) * | 2003-11-17 | 2005-06-23 | Klinikum der Universität München Großhadern-Innenstadt | Leptinantagonist und Verfahren zur quantitativen Messung von Leptin |
| US8969291B2 (en) | 2004-10-08 | 2015-03-03 | Enzo Therapeutics, Inc. | Methods for decreasing leptin levels or activity for treating inflammation |
| US7863240B2 (en) | 2004-10-08 | 2011-01-04 | Enzo Therapeutics, Inc. | Methods and uses of leptin in hepatocellular carcinoma |
| CA2585549A1 (en) | 2004-11-18 | 2006-05-26 | Vib Vzw | Novel type leptin receptor antagonist |
| US7307142B2 (en) * | 2004-11-26 | 2007-12-11 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem | Leptin antagonists |
| US8008443B2 (en) | 2005-04-26 | 2011-08-30 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
| PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
| GB0715216D0 (en) | 2007-08-03 | 2007-09-12 | Asterion Ltd | Leptin |
| DK2356270T3 (da) | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
| MX355060B (es) | 2010-11-17 | 2018-04-03 | Chugai Pharmaceutical Co Ltd | Molecula multiespecifica de union a antigeno que tiene funcion alternativa a la funcion del factor viii de coagulacion sanguinea. |
| MX2013009151A (es) | 2011-02-10 | 2013-08-29 | Roche Glycart Ag | Inmunoterapia mejorada. |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| EP2895513B1 (en) | 2012-09-12 | 2018-05-23 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| ES2678221T3 (es) * | 2013-02-20 | 2018-08-09 | Regeneron Pharmaceuticals, Inc. | Animales no humanos con secuencias de cadena pesada de inmunoglobulina modificadas |
| EP3108255B1 (en) | 2014-02-18 | 2020-08-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway |
| TWI752920B (zh) | 2015-10-12 | 2022-01-21 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| EP4613772A3 (en) | 2016-11-08 | 2025-12-24 | Regeneron Pharmaceuticals, Inc. | Antigen-binding proteins that antagonize leptin receptor |
-
2017
- 2017-11-08 EP EP25187542.3A patent/EP4613772A3/en active Pending
- 2017-11-08 FI FIEP17801273.8T patent/FI3538554T3/fi active
- 2017-11-08 DK DK17801273.8T patent/DK3538554T3/da active
- 2017-11-08 US US15/807,426 patent/US10550192B2/en active Active
- 2017-11-08 EP EP17801273.8A patent/EP3538554B1/en active Active
- 2017-11-08 MY MYPI2019002549A patent/MY191256A/en unknown
- 2017-11-08 RS RS20250925A patent/RS67214B1/sr unknown
- 2017-11-08 MY MYPI2022002957A patent/MY203682A/en unknown
- 2017-11-08 LT LTEPPCT/US2017/060690T patent/LT3538554T/lt unknown
- 2017-11-08 PL PL17801273.8T patent/PL3538554T3/pl unknown
- 2017-11-08 AU AU2017359439A patent/AU2017359439B2/en active Active
- 2017-11-08 SG SG10201913470SA patent/SG10201913470SA/en unknown
- 2017-11-08 KR KR1020197016377A patent/KR102563568B1/ko active Active
- 2017-11-08 WO PCT/US2017/060690 patent/WO2018089532A1/en not_active Ceased
- 2017-11-08 UA UAA201906354A patent/UA127678C2/uk unknown
- 2017-11-08 CN CN201780082335.4A patent/CN110167965A/zh active Pending
- 2017-11-08 ES ES17801273T patent/ES3040144T3/es active Active
- 2017-11-08 JP JP2019523865A patent/JP7042816B2/ja active Active
- 2017-11-08 EA EA201991075A patent/EA201991075A1/ru unknown
- 2017-11-08 MA MA45801A patent/MA45801B1/fr unknown
- 2017-11-08 SM SM20250327T patent/SMT202500327T1/it unknown
- 2017-11-08 PT PT178012738T patent/PT3538554T/pt unknown
- 2017-11-08 MX MX2019005397A patent/MX2019005397A/es unknown
- 2017-11-08 CA CA3043365A patent/CA3043365A1/en active Pending
- 2017-11-08 HR HRP20251165TT patent/HRP20251165T1/hr unknown
- 2017-11-08 SI SI201731619T patent/SI3538554T1/sl unknown
-
2019
- 2019-05-02 IL IL266426A patent/IL266426B/en active IP Right Grant
- 2019-05-03 PH PH12019500988A patent/PH12019500988A1/en unknown
- 2019-05-07 CO CONC2019/0004672A patent/CO2019004672A2/es unknown
- 2019-05-08 CL CL2019001263A patent/CL2019001263A1/es unknown
- 2019-05-08 MX MX2023011233A patent/MX2023011233A/es unknown
-
2020
- 2020-01-07 US US16/736,760 patent/US11535675B2/en active Active
- 2020-01-30 IL IL272358A patent/IL272358B/en unknown
- 2020-03-05 CL CL2020000549A patent/CL2020000549A1/es unknown
- 2020-04-16 CL CL2020001023A patent/CL2020001023A1/es unknown
-
2021
- 2021-12-21 JP JP2021206917A patent/JP2022031969A/ja active Pending
-
2022
- 2022-11-17 US US18/056,411 patent/US20230235068A1/en active Pending
-
2023
- 2023-05-02 JP JP2023076083A patent/JP7611292B2/ja active Active
-
2024
- 2024-05-31 JP JP2024088870A patent/JP2024109952A/ja active Pending
-
2025
- 2025-02-28 AU AU2025201454A patent/AU2025201454A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020504078A5 (enExample) | ||
| FI3538554T3 (fi) | Antigeeniä sitovia proteiineja, jotka antagonisoivat leptiinireseptoria | |
| JP2020528750A5 (enExample) | ||
| JP6681433B2 (ja) | Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト | |
| JP2020510422A5 (enExample) | ||
| JP2019521098A5 (enExample) | ||
| JP2014500009A5 (enExample) | ||
| JP2020501531A5 (enExample) | ||
| JP2020514310A5 (enExample) | ||
| JP2016519650A5 (enExample) | ||
| JPWO2019129221A5 (enExample) | ||
| JP2018506961A5 (enExample) | ||
| EP3400243A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| JP2017535257A5 (enExample) | ||
| JP2013539468A5 (enExample) | ||
| JP2020529835A5 (enExample) | ||
| JP2017519501A5 (enExample) | ||
| JP2015529641A5 (enExample) | ||
| KR20190028716A (ko) | Pd-l1-특이적 항체 및 이를 사용하는 방법 | |
| JP2017532037A5 (enExample) | ||
| JP2009529920A5 (enExample) | ||
| IL299348B1 (en) | Antigen-binding proteins against human papillomavirus and methods of using them | |
| JP2012504401A (ja) | 抗ｃｘｃｒ４抗体および癌治療のためのそれらの使用 | |
| JP2005515963A5 (enExample) | ||
| WO2023206350A1 (en) | Anti-ccr8 antibodies and uses thereof |